文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

英夫利西单抗暴露、粪钙卫蛋白与克罗恩病内镜缓解关系的模型研究

Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease.
PubMed 文献 · Br J Clin Pharmacol · 2020-06-03

本研究基于116例克罗恩病患者的4期剂量递增研究数据,构建群体药代动力学/药效学模型,刻画英夫利西单抗剂量-暴露-生物标志物(粪钙卫蛋白)与内镜缓解的关系。模型预测5 mg/kg英夫利西单抗治疗时内镜缓解率为45%[30-61],升至10 mg/kg仅增至48%[32-63],不支持对所有患者常规采用10 mg/kg诱导剂量。

要点

  • 英夫利西单抗清除率随粪钙卫蛋白升高、白蛋白降低、克罗恩病活动指数升高及抗药抗体存在而增加。
  • 较低的粪钙卫蛋白可提高获得内镜缓解的概率并降低失去缓解的概率。
  • 人群水平上10 mg/kg诱导较5 mg/kg仅轻微提高内镜缓解率,不支持对所有患者常规使用10 mg/kg诱导。

核心结论

  • 基于模型指导、以预设粪钙卫蛋白浓度为目标的英夫利西单抗剂量优化(同时考虑药代和药效变异)可能提高英夫利西单抗治疗有效性。

研究设计与样本

  • 数据来自116例克罗恩病患者的4期剂量递增研究。
  • 构建三个序贯模型:二室群体药代动力学模型连接英夫利西单抗剂量与暴露;间接反应群体药代/药效模型描述暴露对粪钙卫蛋白的抑制效应;一阶马尔可夫群体药效模型连接粪钙卫蛋白与内镜缓解、无内镜缓解及脱落状态间的转换。

主要发现

  • 英夫利西单抗清除率随粪钙卫蛋白升高、白蛋白降低、克罗恩病活动指数升高及抗药抗体存在而增加。
  • 基线粪钙卫蛋白随C反应蛋白升高和血小板计数降低而增加。
  • 较低的粪钙卫蛋白提高获得内镜缓解的概率并降低失去内镜缓解的概率。
  • 在既往无内镜缓解状态下,脱落概率随时间增加。
  • 大的个体间药代和药效变异导致平坦的剂量-反应曲线。

关键数值与推荐

  • 5 mg/kg英夫利西单抗时预测达到内镜缓解的患者比例为45%[30-61](中位数[四分位距],n=50 000),观察数据约为46%。
  • 10 mg/kg诱导剂量模拟预测内镜缓解比例增至48%[32-63]。

临床怎么用

  • 人群水平上10 mg/kg诱导较5 mg/kg的获益很小,不支持对所有患者常规采用10 mg/kg诱导剂量。
  • 可基于模型指导、以预设粪钙卫蛋白浓度为目标的英夫利西单抗剂量优化,同时考虑药代和药效变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Evidence for the benefits of pharmacokinetic (PK) and pharmacodynamic (PD) monitoring of infliximab in patients with Crohn's disease (CD) remains scarce. We aimed to develop a population (pop)PK/PD model to characterise the infliximab dose-exposure-biomarker-response (faecal calprotectin [fCal] and endoscopic remission [ER]) relationship. METHODS: Data were obtained from 116 patients with CD in a phase 4 dose-escalation study. Three sequential models were developed: a 2-compartment popPK model linking infliximab dose to exposure; an indirect response popPK/PD model describing the inhibitory effect of infliximab exposure on fCal; and a first-order Markov popPD model linking fCal to transitions between states of ER, no ER and dropout. RESULTS: Infliximab clearance increased with increasing fCal, decreasing albumin, increasing CD activity index and presence of anti-drug antibodies. Baseline fCal increased with increasing C-reactive protein and decreasing platelet count. Lower fCal increased the probability of attaining ER and decreased the probability of losing ER. Probability of dropping out given an earlier state of absence of ER increased with time. Large interpatient PK and PD variability resulted in a flat dose-response curve. Predicted fraction of patients achieving ER was 45% [30-61] (median [interquartile range], n = 50 000) when on 5 mg/kg infliximab (~46% observed in data). Simulations with 10 mg/kg induction doses predicted an increase to 48% [32-63]. This minor benefit at the population level argues against systematic 10 mg/kg induction dosing in all patients. CONCLUSION: Model-informed infliximab dose optimisation towards a predefined fCal concentration (while accounting for PK and PD variability) may improve effectiveness of infliximab therapy.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Dreesen E, Berends S, Laharie D, et al. Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease. Br J Clin Pharmacol. 2020. PMID: 32415677. doi:10.1111/bcp.14364

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。